Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 08, 2024 16:15 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 7, 2024, the Company granted four new employees 12,900 restricted stock units (RSUs)...
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
November 07, 2024 06:00 ET
|
Esperion Therapeutics, Inc.
– Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – – Total Retail Prescription Equivalents Increased 12% and New...
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
November 04, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on...
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
October 31, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that one featured presentation in the Late Breaker/Featured Science track and three poster presentations...
Esperion to Report Third Quarter 2024 Financial Results on November 7
October 24, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024....
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
October 02, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
– Patients Prescribed Bempedoic Acid, As Well As Bempedoic Acid and Ezetimibe, With or Without Other Lipid Lowering Therapies, Showed A One-Third Relative Reduction in Low-Density LDL-C From...
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
September 25, 2024 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on September 23, 2024, the Company granted one new employee 3,500 restricted stock units (RSUs)...
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
September 05, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Cantor Global Healthcare Conference on...
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
September 03, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially...
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
August 26, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 26th Annual Global Investment...